Nephrogenic systemic fibrosis: Chronic imaging findings and review of the medical literature

Skeletal Radiology

Volumn 37, Issue 5, 2008, Pages 457-464

  Weigle, Jeffrey P ^a,b   Broome, Dale R ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b Bureau of Medicine and Surgery   (United States)

Author keywords

Gadolinium; MR imaging; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis; Renal failure; Skeletal scintigraphy

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; METHOXSALEN; NARCOTIC ANALGESIC AGENT; OXIDRONATE TECHNETIUM TC 99M; PREDNISONE; THIOSULFATE;

ADULT; ANKYLOSIS; ARTHRALGIA; ARTICLE; BONE PAIN; BONE RADIOGRAPHY; BONE SCINTISCANNING; CALCIFICATION; CASE REPORT; CONTRACTURE; DISABILITY; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHEMA; FEMALE; HETEROTOPIC OSSIFICATION; HUMAN; JOINT SWELLING; KIDNEY TRANSPLANTATION; LONG BONE; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEDICAL LITERATURE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOSTEUM; PHOTOTHERAPY; PHYSIOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; SKIN BIOPSY; SKIN FIBROSIS; SKIN INDURATION; SKINFOLD; SYSTEMIC DISEASE;

ADULT; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM DTPA; HUMANS; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MUSCULOSKELETAL DISEASES;

EID: 43549107011     PISSN: 03642348     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00256-008-0464-1     Document Type: Article

References (57)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit, PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001.
2. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy; an autopsy case and review of the literature. Arch Path Lab Med 2006; 130: 209-212.
3. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005; 46: 763-765.
4. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108. Erratum 2006; 21: 1745.
5. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362.
6. Broome DR, Girguis MS, Baron PW, Cottrelll AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis-why radiologists should be concerned. AJR Am J Roentgenol 2007; 188: 586-592.
7. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157.
8. Cheng S. Abramova L, Saab G, et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents. MMWR 2007; 56: 137-141.
9. Gremmels JM, Kirk GA. Two patients with abnormal muscle uptake of Tc-99 m hydroxymethylene diphosphonate following liver transplant: nephrogenic fibrosing dermopathy and graft vs host disease. Clin Nucl Med 2004; 29: 694-697.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
11. Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging 2007; 7: 130-137.
12. Cowper SE. Nephrogenic fibrosing dermopathy. 2001-2007. Available at http://www.icnfdr.org. Accessed 20 October 20 2007.
13. Chesney J, Bucala R. Peripheral blood fibrocytes: mesenchymal precursors cells and the pathogenesis of fibrosis. Curr Rheumatol Rep 2000; 2: 501-505.
14. Quan T, Cowpers S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 35: 598-606.
15. Nowack R, Wachtler P. Scleroderma-like syndrome triggered by gadolinium. Nephrol Dial Transplant 2006; 21: 3344, Nov.
16. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007; 56: 27-30.
17. High WA, Ayers RA, Chandler J, Zito, G, Cowpers SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21-26.
18. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007; 42: 139-145.
19. Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. J Am Acad Dermatol 2007; 57: 105-111.
20. Richmond H, Zwerner J, Kim Y, Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007; 143: 1025-1030.
21. Yerram P, Saab G, Karuparthi PR, Hayden MR, Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; 2: 258-263.
22. Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007; 2: 199-205.
23. Moreno-Romero JA, Segura S, Mascaro JM Jr, et al. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007; 157: 783-787.
24. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22: 3174-3178.
25. Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. Clin Exp Dermatol 2007; 32: 353-358.
26. Swaminathan S, Horn TD, Pellowski D, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007; 16; 357: 720-722.
27. Deo A, Fogel M, Cowpers SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007; 2: 264-267.
28. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007; 245: 168-175.
29. Introcaso CE, Hivnor C, Cowper S, Wirth VP. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol 2007; 46: 447-452.
30. Plamondon I, Samson C, Watters AK, et al. Nephrogenic systemic fibrosis: more hard times for renal failure patients. Nephrol Ther 2007; 3: 152-156.
31. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22: 3179-3185.
32. Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007; 56: 3433-3441.
33. Cheung PP, Doria Raj AK. Nephrogenic fibrosing dermopathy: a new clinical entity mimicking scleroderma. Intern Med J 2007; 37: 139-141.
34. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007; 26: 1198-1203.
35. Rydahl C, Thomsen HS, Marckmann P, et al. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium (Gd) containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141-144.
36. Clorius S, Technau K, Watter T, et al. Nephrogenic systemic fibrosis following exposure to gadolinium-containing contrast agent. Clin Nephrol 2007; 68: 249-252.
37. Saussereau E, Lacroix C, Cattaneo A, Mahieu L, Goulle JP. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int 2007; [Epub ahead of print].
38. Tsai CW, Chao CC, Wu VC, Hsiao CH, Chen YM. Nephrogenic fibrosing dermopathy in a peritoneal dialysis patient. Kidney Int 2007; 72: 1294.
39. Krous HF, Breisch E, Chadwick AE, Pickney L, Malicki DM, Benador N. Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lympoma, Ewing's sarcoma, end-stage rnela disease, hemodialysis. Pediatr Dev Pathol 2007; 10: 395-402.
40. Kintossou R, D'Incan M, Chauveau D, et al. Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis: role of gadolinium? Ann Dermatol Venereol 2007; 134: 667-671.
41. Evenepoel P, Zeegers M, Segaert S, et al. Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant 2004; 19: 469-473.
42. Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2004; 19: 467-470.
43. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6: 2212-2217.
44. Dharnidharka VR, Wesson S, Fennell RS. Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 2007; 22: 1395.
45. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007; 7: 2425-2432.
46. Kanal E, Broome DR, Martin DR, Martin DR, Thomsen HS. Response to the FDA's May 23, 2007, Nephrogenic Systemic Fibrosis Update Radiology. Radiology 2008; 246: 11-14.
47. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004; 50: 2660-2666.
48. Parson AC, Yosipovitch G, Sheehan DJ, Sangueza OP, Greenberg CS, Sane DC. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 2007; 29: 433-436.
49. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006; 20: 563-576.
50. U.S. Food and Drug Administration. Information for healthcare professionals: gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MulitiHance, Omniscan, OptiMARK, ProHance). http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm. Published June 2006. Updated 23 May 23 2007. Accessed 20 October 2007.
51. Commission of Human Medicines. Nephrogenic systemic fibrosis (NSF) with gadolinium-containing magnetic resonance imaging (MRI) contrast agents - update. http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSecondary= true&ssDocName=CON2031543&ssTargetNodeId=221. Published 26 June 2007. Updates 19 July 19 2007. Accessed 30 November 2007.
52. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dialysis 2007; 20: 217-219.
53. Edsall LC, English JC, Teague MW, Patterson JW. Calciphylaxis and metastatic calcifications associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2005; 31; 247-253.
54. Taylor E, Henderson J, Rennke H, Magee CC. Traumatic calcinosis cutis in a dialysis patient. Am J Kidney Dis 2004; 44; 18-21.
55. Hershko K, Hull C. Ettefagh L, et al. A variant of nephrogenic fibrosing dermopathy with osteoclast-like giant cells: a syndrome of dysregulated matrix remodeling? J Cutan Pathol 2004; 31: 262-265.
56. Ruiz-Genao DP, Pascual-Lopez MP, Fraga S, Araguez M, Garcia-Diez A. Osseous metaplasia in the setting of nephrogenic fibrosing dermopathy. J Cutan Pathol 2005; 32: 172-175.
57. Broome DR, Cottrell AC, Kanal E. Response to "Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?" AJR Am J Roentgenol 2007; 189: W234-W235.